Completed PHASE3 INTERVENTIONAL 2-arm NCT00241670

Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid

Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid (5-ALA) vs. Conventional Resection

Sponsor: medac GmbH

Conditions Brain Cancer Brain Tumor, Primary Brain Tumors Cancer of Brain Primary Brain Tumors

Interventions 5-aminolevulinic acid (5-ALA)

Updated 5 times since 2017 Last updated: Apr 25, 2012 Started: Oct 31, 1999 Primary completion: Jul 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00241670, this PHASE3 trial focuses on Brain Cancer and Brain Tumor, Primary and remains completed. Sponsored by medac GmbH, it has been updated 5 times since 1999, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

medac GmbH

Data source: medac GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.